REG - Physiomics PLC - Physiomics Awarded New Contract by Numab

PhysiomicsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260128:nRSb6161Qa&default-theme=true

RNS Number : 6161Q  Physiomics PLC  28 January 2026

28 January 2026

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract by Numab Therapeutics

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a new contract with
its valued and long-standing client, Numab Therapeutics AG ("Numab
Therapeutics").

This project reflects the continued application of Physiomics' modelling
expertise across Numab Therapeutics' pipeline to accelerate the development of
innovative therapies, building further on the already well-established
relationship.

Numab Therapeutics is a biopharmaceutical company focused on the discovery and
development of next-generation multispecific antibody-based therapeutics for
inflammation and oncology. Under this new contract, Physiomics will develop a
pharmacokinetic-pharmacodynamic (PK/PD) model to inform the Target Candidate
Profile of a key asset in Numab Therapeutics' Immunology and Inflammation
pipeline. The modelling work is intended to support data-driven
decision-making at an early stage of development and is expected to commence
imminently, with completion anticipated within Q2 2026.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to continue our collaboration with Numab Therapeutics and to
have the opportunity to contribute further insights across its promising
pipeline. In particular, this work allows us to support earlier research and
development decisions through quantitative, data-driven approaches, helping to
shape candidate profiles at a critical stage and thus streamlining drug
development journeys."

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 140 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTFLFFDLFIDFIR



            Copyright 2019 Regulatory News Service, all rights reserved